2026年2月24日 / 美国东部时间上午10:08 / 哥伦比亚广播公司新闻
诺和诺德周二表示，自明年起将大幅下调旗下Wegovy和Ozempic的价格，最高降幅达50%，这凸显了制药公司在争夺减肥药物消费者方面的竞争日益激烈。
这家丹麦制药商称，从2027年1月开始，这些药物每月定价为675美元，其中Wegovy降价50%，Ozempic降价35%。诺和诺德还将以相同价格销售Rybelsus——一种用于成人2型糖尿病患者的口服药物，有时也被用于减肥。
诺和诺德做出这一决定之际，正面临礼来公司的竞争，后者销售Mounjaro和Zepbound（均为常用减肥注射剂），同时还有其他所谓的GLP-1类治疗药物也在陆续上市。
Wegovy和Ozempic是在Trumprx.gov网站上折扣销售的数十种药物之一。该网站是特朗普政府推出的新在线平台，让消费者可以直接获取约40种药物的更低价格。
去年11月，诺和诺德还宣布了Wegovy和Ozempic的新定价计划，以降低部分客户的用药成本。
该公司周二将这一决定描述为提高药物可及性的举措，在新闻稿中指出，希望降低高免赔额保险计划患者的自付费用。
诺和诺德美国业务执行副总裁杰米·米勒在声明中表示：“私人和公共医保支付方以及患者都希望获得药物，并一直呼吁降低药品定价。”
该制药公司称，此次降价不会影响其“直接面向患者”的价格，即一些制造商直接向消费者提供的折扣价格。
编辑：Alain Sherter
Novo Nordisk to slash Wegovy prices by 50%, Ozempic by 35%
February 24, 2026 / 10:08 AM EST / CBS News
Novo Nordisk said Tuesday it will slash its prices for Wegovy and Ozempic beginning next year by up to 50%, highlighting the growing competition among pharmaceutical firms for customers seeking weight-loss drugs.
The Danish drugmaker said it plans to offer the medicines for $675 per month starting in January 2027, representing a 50% reduction in price for Wegovy and a 35% reduction for Ozempic. Novo Nordisk will also sell Rybelsus, a pill for adults with type 2 diabetes that is sometimes used for weight loss, for the same price.
Novo Nordisk’s decision comes as it competes with Eli Lilly, which sells Mounjaro and Zepbound, injectable medications commonly used for weight-loss, and with providers of other so-called GLP-1 treatments coming to market.
Wegovy and Ozempic are among dozens of drugs sold at a discount on Trumprx.gov, a new online platform launched by the Trump administration that gives consumers direct access to lower prices for roughly 40 drugs.
In November, Novo Nordisk also announced a new pricing plan for Wegovy and Ozempic to reduce costs for some customers.
The company on Tuesday framed its decision as a way to enhance affordability, noting in a press release that it wants to lower out-of-pocket costs for customers with high-deductible insurance plans.
“Private and public payers, as well as patients, want access and have been calling for lower list prices,” Jamey Miller, executive vice president of U.S. operations for Novo Nordisk, said in a statement.
The pharmaceutical company said the price cuts will not impact its “direct-to-patient” prices, the discounted rates that some manufacturers offer straight to consumers.
Edited by Alain Sherter
发表回复